Compounds > technetium tc 99m sestamibi
Page last updated: 2024-08-16

technetium tc 99m sestamibi and Benign Monoclonal Gammopathies

technetium tc 99m sestamibi has been researched along with Benign Monoclonal Gammopathies in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bhave, A; Lele, RD; Luthra, K1
Bacovský, J; Buriánková, E; Formánek, R; Koranda, P; Minarík, J; Myslivecek, M; Scudla, V; Zapletalová, J1

Other Studies

2 other study(ies) available for technetium tc 99m sestamibi and Benign Monoclonal Gammopathies

ArticleYear
Tc 99m Sestamibi Scanning in Multiple Myeloma--a New look with SPECT-CT.
    The Journal of the Association of Physicians of India, 2014, Volume: 62, Issue:9

    Topics: Female; Follow-Up Studies; Humans; Male; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Plasmacytoma; Radionuclide Imaging; Radiopharmaceuticals; Recurrence; Remission Induction; Technetium Tc 99m Sestamibi

2014
[18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2010, Volume: 23, Issue:5

    Topics: Adult; Aged; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Positron-Emission Tomography; Radiography; Radiopharmaceuticals; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed

2010